Loading...
ASH congress 20222025-01-27T17:21:03+01:00

ASH 2022 – hybrid

Lecture Board: Othman Al-Sawaf, MD; Chan Cheah, DMSc; Alex F. Herrera, MD; Elisabeth Koller, MD; Constantine Tam, MBBS, MD; Stefan Vogt, MD; Michael Wang, MD; Moshe Yair Levy, MD
Medical Writer: Judith Moser, MD
Publishing Editor: Anna Fenzl, PhD

DOWNLOADS

All downloads from ASH 2022

memo-inHaematology-ASH-2022-Slidekit

Slidekit BTK inhibition and BCL2 inhibition in B-cell malignancies and AML

ASH 2022 English Download

Full report (english)

EXPERT VIDEOS

All video interviews from ASH 2022

Shirley D’Sa discusses the results of the first clinical trial investigating checkpoint inhibition in relapsed/refractory Waldenström’s macroglobulinemia as well as other immunotherapeutic agents or combinations that might be worth investigating in this setting and explains the association of type I cryoglobulinemia with WM, IgM monoclonal gammopathy of undetermined significance or non-Hodgkin Lymphoma.

Go to Top